Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
April 30, 2020 16:05 ET
|
Novan, Inc.
Enrollment of first patient targeted for September 2020Top line results expected late in the second quarter of 2021 based on anticipated timeline MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE)...
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
April 20, 2020 16:05 ET
|
Novan, Inc.
Engages H.C. Wainwright & Co. as strategic and financial advisorNITRICIL™ nitric oxide technology platform has enabled multiple early and late-stage pipeline opportunities in dermatology, women’s...
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
April 03, 2020 08:15 ET
|
Novan, Inc.
Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
March 23, 2020 08:15 ET
|
Novan, Inc.
Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including...
Novan Provides SB206 Program and Business Update
February 06, 2020 08:30 ET
|
Novan, Inc.
FDA grants Type C meeting for SB206 to be held on April 1, 2020Last subject completes last visit, Week 24 safety evaluationAdditional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb....
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
January 02, 2020 16:15 ET
|
Novan, Inc.
Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern TimeFocus of call: top-line efficacy data and sensitivity analyses MORRISVILLE, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) --...
Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology
October 08, 2019 08:30 ET
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical...
Novan Hires Michelle Patterson as Vice President of Project Management
September 03, 2019 16:05 ET
|
Novan, Inc.
Underscores Company’s preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results...
Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment
August 13, 2019 08:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has recently completed patient recruitment in the Company’s...
Novan SB206 Phase 3 Molluscum Pivotal Program Update
July 11, 2019 08:15 ET
|
Novan, Inc.
More than 50 percent of total expected patients now enrolledVirtually all of the clinical sites now active Discipline and execution focus remain of equal importance to recruitment activity ...